Basking Biosciences Takes Major Step with BB-025 Phase 1 Study to Reverse Stroke Treatment BB-031

Basking Biosciences Moves Forward with Innovative Stroke Treatment

Basking Biosciences, a pioneering clinical-stage biopharmaceutical firm, has taken a significant step in stroke treatment innovation by initiating the first human trials of BB-025. This novel agent, a rapid-acting reversal therapy, is specifically designed to counteract the effects of BB-031, the company’s leading investigational therapy for acute ischemic stroke (AIS).

Understanding the Breakthrough

On November 12, 2025, Basking announced that the first participants have been successfully dosed in a Phase 1 clinical trial for BB-025, which is being conducted in Australia. This study aims to assess the safety, tolerability, and pharmacodynamic properties of the drug, marking an essential milestone in Basking's mission to transform the standard of care in stroke treatment.

BB-025 works by binding to BB-031, thereby neutralizing its effects. This innovative approach allows clinicians to have a mechanism to reverse treatments should complications arise, such as bleeding or the need for urgent surgical procedures. Dr. Shahid M. Nimjee, co-founder and CMO of Basking, emphasized that this capability represents a major advancement in stroke therapy. Although the majority of patients treated with BB-031 may not need reversal, having this option enhances the safety and flexibility of stroke care.

Phase 1 Study Design

The Phase 1 study is structured to first evaluate BB-025 in single ascending-dose cohorts of healthy volunteers. Participants will be randomized to receive either BB-025 or a placebo. After establishing the safety profile of BB-025, the next cohorts will receive BB-031 followed by BB-025, to determine how quickly and effectively BB-025 can reverse the action of BB-031 in a clinical setting.

Julia C. Owens, Ph.D., CEO of Basking, highlighted the importance of this trial as integral to the development strategy of the company's products. By building on the advancements achieved with BB-031, BB-025 aims to provide greater assurance to healthcare professionals administering stroke treatments.

The Science Behind BB-031 and BB-025

BB-031 is an investigational RNA aptamer targeting von Willebrand Factor (vWF), critical in platelet adhesion and thrombus formation. This innovative design makes BB-031 a targeted, effective thrombolytic therapy aimed at safely dissolving clots in AIS patients. The synergistic pairing of BB-031 and BB-025 creates an